Quick Answer
Alzamend Neuro, Inc. reported Total Assets of $4.60 million for the year ending 2025.
- Alzamend Neuro, Inc. showed an increase of +628.8% in Total Assets from 2024 to 2025.
- This data is from Alzamend Neuro, Inc.'s annual report (Form 10-K), filed with the SEC on July 22, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $16.82 million | Q4 2021: $14.50 million | Q1 2022: $12.43 million | Q3 2022: $12.21 million | Q4 2022: $10.42 million | Q1 2023: $8.50 million | Q3 2023: $2.63 million | Q4 2023: $983.6 thousand | Q1 2024: $782.6 thousand | Q3 2024: $1.67 million | Q4 2024: $5.01 million | Q1 2025: $4.18 million | Q2 2025: $4.60 million | Q3 2025: $6.33 million | Q4 2025: $5.09 million.
- Over the full 6 years of available data (2020 to 2025), Alzamend Neuro, Inc.'s Total Assets has grown by 153.7%.
- Historical annual values: Fiscal year 2025: $4.60 million | Fiscal year 2024: $631.6 thousand | Fiscal year 2023: $5.92 million | Fiscal year 2022: $14.52 million | Fiscal year 2021: $2.91 million | Fiscal year 2020: $1.81 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: